C92.02 Insurance Policy Changes

ICD-10 C92.02 is officially defined as "Acute myeloblastic leukemia, in relapse." code C92.02 is referenced in 12 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C92.02 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 15, 2026Medium impact
Avelumab (Bavencio) (CPB 0916, reviewed 2026-10-14)
Aetna considers avelumab (Bavencio) medically necessary for commercial plan members with Merkel cell carcinoma, renal cell carcinoma in combination with axitinib, urothelial carcinomas, gestational trophoblastic neoplasia, endometrial carcinoma, thymic carcinoma, extranodal NK/T-cell lymphoma, colorectal adenocarcinoma, and small bowel adenocarcinoma when the criteria for each indication are met. Precertification of avelumab is required for all Aetna participating providers and members in applicable plan designs, and members who have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy are not eligible. Aetna considers avelumab experimental, investigational, or unproven for all other indications, including breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, and pancreatic cancer.
Aetna · Identified Oct 4, 2026Medium impact
Hematopoietic Cell Transplantation for Selected Leukemias (CPB 0640, reviewed 2026-09-11)
Aetna's clinical policy bulletin CPB 0640 (reviewed 2026-09-11, first detected here 2026-10-04, so this is historical material) sets when stem cell transplant is covered for acute lymphocytic, myeloid and other leukemias. It covers allogeneic transplants for most of these leukemias when the transplant center's criteria are met, but it lists autologous transplant for ALL, CMML and JMML, tandem transplants for ALL, repeat transplants for AML that has not gone into remission, hepcidin testing and micro-transplantation as experimental. The notice gives no new effective date and does not say what changed in this review, so confirm the current bulletin with Aetna before acting on it.
Aetna · Identified Oct 4, 2026Medium impact
Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2026-09-23)
Aetna's Clinical Policy Bulletin 0627 covers allogeneic hematopoietic cell transplantation for severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria, and pure red cell aplasia when the transplanting institution's selection criteria are met. Where institution criteria are not available, Aetna considers allogeneic transplant medically necessary for severe aplastic anemia with marrow cellularity less than 25% (or 25% to 50% with less than 30% hematopoietic cells) and at least 2 of 3 peripheral blood cytopenias, and for repeat allogeneic transplant after primary graft failure, failure to engraft or rejection. Autologous hematopoietic cell transplantation for these conditions is considered experimental, investigational or unproven.
Aetna · Identified Oct 1, 2026Medium impact
Donor Lymphocyte Infusion (CPB 0638, reviewed 2026-09-29)
Aetna considers donor lymphocyte infusion medically necessary for persons who have had a prior medically necessary allogeneic bone marrow or peripheral stem cell transplantation. Several uses are considered experimental, investigational, or unproven, including GCSF-stimulated donor lymphocyte infusions for relapsed disease, intrathecal donor lymphocyte infusion, modified donor lymphocytes, reduced-dose infusion for Epstein-Barr virus-related post-transplant lymphoproliferative disease, pre-transplant infusion of extracorporeal photochemotherapy-treated donor lymphocytes for solid organ transplant, and donor lymphocyte-derived natural killer cells for melanoma. The policy does not apply to FDA-approved chimeric antigen receptor therapy, which is addressed in CPB 0920 and CPB 0924.
Aetna · Identified Aug 18, 2026Medium impact
Tisagenlecleucel (Kymriah) (CPB 0920, reviewed 2026-02-24)
Aetna Clinical Policy Bulletin 0920 sets the commercial medical coverage criteria for tisagenlecleucel (Kymriah), a CD19-directed autologous CAR T-cell therapy. Aetna considers it medically necessary for relapsed or refractory B-cell precursor acute lymphoblastic leukemia in members under 26 years of age, for specified relapsed or refractory adult B-cell lymphomas (including DLBCL and follicular lymphoma) under stated criteria, for ALK-positive large B-cell lymphoma if CD19-positive, and for histologic (Richter) transformation to DLBCL under stated criteria. Aetna considers all other indications experimental, investigational, or unproven, including adult ALL, AML, CLL, Hodgkin lymphoma, plasma cell disorders, and repeat administration of the therapy.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2025-12-11)
Aetna considers allogeneic hematopoietic cell transplantation medically necessary for severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria and pure red cell aplasia when members meet the transplanting institution's selection criteria, and sets specific disease criteria when the institution has none. Aetna considers repeat allogeneic stem cell transplantation medically necessary for primary graft failure, failure to engraft or rejection in these conditions. Autologous hematopoietic cell transplantation is considered experimental, investigational or unproven for these indications.
Aetna · Identified Aug 14, 2026Medium impact
Donor Lymphocyte Infusion (CPB 0638, reviewed 2025-11-12)
Aetna considers donor lymphocyte infusion (DLI) medically necessary for persons who have had a prior, medically necessary allogeneic bone marrow or peripheral stem cell transplantation. Aetna considers these uses experimental, investigational, or unproven: GCSF-stimulated DLI for relapsed disease after allogeneic hematopoietic cell transplantation, intrathecal DLI, modified donor lymphocytes (such as depleted, expanded, T-cell depleted, CAR-modified or genetically modified cells), pre-transplant infusion of extracorporeal photochemotherapy-treated donor lymphocytes to prevent graft rejection after solid organ transplantation, reduced-dose DLI for Epstein-Barr virus-related post-transplant lymphoproliferative disease, and donor lymphocyte-derived natural killer cells for melanoma. The policy does not apply to FDA-approved CAR T therapy, which involves modification of autologous lymphocytes.
Aetna · Identified Aug 13, 2026Medium impact
Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)
Aetna considers palivizumab (Synagis) medically necessary for commercial medical plans for up to 5 doses per RSV season to prevent serious lower respiratory tract disease caused by RSV, when a member has a qualifying diagnosis such as prematurity, chronic lung disease of prematurity, hemodynamically significant congenital heart disease, cystic fibrosis or profound immunocompromise and the associated criteria are met. Palivizumab is excluded for members who have received nirsevimab-alip (Beyfortus) in the same RSV season. The American Academy of Pediatrics stated that in July 2025 it no longer routinely recommends using Synagis.
Aetna · Identified Aug 13, 2026Medium impact
Clofarabine (CPB 0867, reviewed 2025-12-24)
Aetna considers clofarabine medically necessary for relapsed or refractory acute myeloid leukemia, for specified acute lymphoblastic leukemia indications including relapsed or refractory pediatric disease, for Langerhans cell histiocytosis in members 18 years of age or younger, and as conditioning for hematopoietic cell transplantation under the listed regimens. Continuation of clofarabine therapy is considered medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen. All other indications, including B-cell lymphoma, breast cancer, Ewing sarcoma and myelodysplastic syndrome, are considered experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Azacitidine (CPB 0960, reviewed 2026-06-12)
Aetna considers azacitidine (Vidaza or generic azacitidine) medically necessary for myelodysplastic syndromes, acute myeloid leukemia, accelerated or blast phase myeloproliferative neoplasm, blastic plasmacytoid dendritic cell neoplasm when used in combination with venetoclax, and myelodysplastic syndrome/myeloproliferative neoplasms overlap neoplasms. Peripheral T-cell lymphoma, including angioimmunoblastic T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, and follicular T-cell lymphoma, is considered medically necessary only when azacitidine is used as subsequent therapy for relapsed or refractory disease and as a single agent. All other indications are considered experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for FLT3, NPM1, CEBPA, IDH1, and IDH2 Variants in Cytogenetically Normal Acute Myeloid Leukemia
Genetic testing for FLT3 internal tandem duplication (FLT3-ITD), NPM1, CEBPA, IDH1 and IDH2 variants may be considered medically necessary in cytogenetically normal acute myeloid leukemia (AML). Genetic testing for these variants is considered investigational in all other situations, and testing for FLT3 tyrosine kinase domain (FLT3-TKD) variants is considered investigational. Testing for FLT3, NPM1 and CEBPA variants to detect minimal residual disease is also considered investigational, and the testing is intended to guide management decisions in individuals who would receive treatment other than low-dose chemotherapy or best supportive care.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
A 07/24/2026 review revised the policy statement on allogeneic HCT using a reduced-intensity conditioning regimen to remove the reference to Policy Guidelines, and the Code Reference section was updated to remove ICD-9 procedure and diagnosis codes. Allogeneic HCT with myeloablative conditioning may be considered medically necessary for poor- to intermediate-risk AML in first complete remission and for certain refractory or relapsed AML, while autologous HCT may be considered for AML in CR1 or beyond, or relapsed AML, in individuals who are not candidates for allogeneic HCT.

Watch C92.02

Get one email when a payer policy names C92.02, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C92.02?

There are 12 tracked policy changes affecting code C92.02, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C92.02?

Payers that have issued tracked updates for code C92.02 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code C92.02 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C92.02. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C92.02?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Avelumab (Bavencio) (CPB 0916, reviewed 2026-10-14)

Hematopoietic Cell Transplantation for Selected Leukemias (CPB 0640, reviewed 2026-09-11)

Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2026-09-23)

Donor Lymphocyte Infusion (CPB 0638, reviewed 2026-09-29)

Tisagenlecleucel (Kymriah) (CPB 0920, reviewed 2026-02-24)

Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2025-12-11)

Donor Lymphocyte Infusion (CPB 0638, reviewed 2025-11-12)

Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)

Clofarabine (CPB 0867, reviewed 2025-12-24)

Azacitidine (CPB 0960, reviewed 2026-06-12)

Genetic Testing for FLT3, NPM1, CEBPA, IDH1, and IDH2 Variants in Cytogenetically Normal Acute Myeloid Leukemia

Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

What insurance policy changes affect code C92.02?

Which payers have updated policy for code C92.02?

How do I get notified when code C92.02 policy changes?

Why do payers change policies for code C92.02?